Literature DB >> 2106548

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

U Hopf1, B Möller, D Küther, R Stemerowicz, H Lobeck, A Lüdtke-Handjery, E Walter, H E Blum, M Roggendorf, F Deinhardt.   

Abstract

The natural course of chronic hepatitis non-A, non-B (HNANB) was documented for 3-20 yr (mean 8 yr) in 86 patients, who attended our special ambulance between 1981 and 1988. Sixty five of the 86 patients (75%) were positive for circulating antibodies against hepatitis C virus (HCV) (anti-HCV). Twenty four patients had chronic posttransfusion (PT)-HNANB (18 anti-HCV-positive; 75%), and 62 patients had sporadic (S)-HNANB (47 anti-HCV-positive; 75%). Twenty nine per cent of patients with chronic PT-HNANB had sustained normalization of aminotransferases after a period up to 5 yr, 55% demonstrated chronic persistent hepatitis (CPH) and 16% progressed to chronic active hepatitis (CAH) with transition to cirrhosis. In the group with chronic S-HNANB, 2% of patients showed remission, 43% had stable CPH and 55% progressed to CAH or cirrhosis. However, development of cirrhotic complications required many years. Transition from CAH to CPH or remission was not observed. The results indicate that 75% of both patients groups with chronic PT- and S-HNANB are infected with the same agent, of which antibodies are detected by the new anti-HCV assay. There was no statistical association between the severity of the disease and the presence of anti-HCV. The different proportions of progressive courses in chronic PT- and S-HNANB might be explained by the patient recruitment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106548     DOI: 10.1016/0168-8278(90)90075-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  32 in total

1.  Hepatitis C virus infection in cocaine users--a silent epidemic.

Authors:  H H Harsch; J Pankiewicz; A S Bloom; C Rainey; J K Cho; L Sperry; E A Stein
Journal:  Community Ment Health J       Date:  2000-06

Review 2.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

3.  Intrafamilial transmission of hepatitis C virus in Japan.

Authors:  K Michitaka; M Onji; N Horiike; K Kajino; I Saito; T Miyamura; Y Ohta
Journal:  Gastroenterol Jpn       Date:  1991-10

Review 4.  Patterns of progression: unpredictability and risk of decompensated cirrhosis.

Authors:  N C Tassopoulos
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Authors:  Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

6.  Hepatitis C virus RNA genome in plasma of patients with non-A, non-B hepatitis.

Authors:  N Enomoto; N Takada; S Takase; A Takada; T Date
Journal:  Gastroenterol Jpn       Date:  1991-02

Review 7.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

8.  Association between Helicobacter pylori infection and cirrhosis in patients with chronic hepatitis C virus.

Authors:  Dulciene Maria Magalhães Queiroz; Andreia Maria Camargos Rocha; Gifone Aguiar Rocha; Sarah Maria Singulano Cinque; Adriana Gonçalves Oliveira; Alicia Godoy; Hugo Tanno
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

9.  Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha.

Authors:  J C Booth; G R Foster; U Kumar; R Galassini; R D Goldin; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

10.  Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.

Authors:  Uwe Siebert; Gaby Sroczynski
Journal:  Ger Med Sci       Date:  2003-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.